Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

DOI Full Paper Access

30

Citations

16

References

2020

Year

Christoph D. Spinner, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans‐Jürgen Stellbrink, Ivanka Krznaric, Stephan Scholten, Björn‐Erik Ole Jensen, Christoph Wyen,

Open Forum Infectious Diseases

Abstract

Switching to DTG + bDRV was noninferior to continuing 3DR in subjects already treated with bDRV.

References

	Year	Citations

Page 1